Tumor-infiltrating lymphocytes (TILs)

Cellular transformation induces phenotypically distinct populations of tumor-infiltrating T cells
Zheng et al. 2017a Cell 169: 1342–1356
Azizi et al. 2018 Cell 174(5): 1293–1308
Simoni et al. 2018 Nature 557: 575–579
Zhang et al. 2018g Nature 564: 268–272
Zheng et al. 2021c Science 374: 1462

CD8+ T cells in tumors predict better outcomes. They are key for Immune Checkpoint Inhibitors (ICIs) Therapy
Wang et al. 2021o Journal for ImmunoTherapy of Cancer 9: e003100

In addition, ILTCKs are also included
Dadi et al. 2016 Cell 164: 365–377

ILTCKs are alfa/beta T cell receptor (TCR)-positive FCER1G-expressing innate T cells with high cytotoxic potential
Dadi et al. 2016 Cell 164: 365–377

Absence of Tumor-infiltrating lymphocytes (TILs) = a marker of poor efficacy of immunotherapies
Gajewski et al. 2013

Recruitment of Tumor-infiltrating lymphocytes (TILs) due to local production of CCL19, CCL17, CCL22, CXCL-13 & IL-16
Fridman et al. 2012

TILs can be isolated and expanded from tumors simply by Excising the Tumor Mass and Dissociating Cells into Single-cell Suspensions or Tumor Fragments
Restifo et al. 2012

TILs are restrained in vivo by immunosuppressive molecules
Restifo et al. 2012

CD8 + TIL treated with an anti-galectin-3 antibody had an increased Interferon Type II (IFN Type II) / Interferon Gamma (IFN-g) secretion, but also CD4 + TIL

CD4 required for maintenance of CD8+ numbers and CTL infiltration of tumor
Marzo et al. 2000

see also:
Cancer Immunotherapy / Immuno-Oncology